Literature DB >> 19434322

Warthin tumor: a curious entity--case reports and review of literature.

Alexandra Faur1, Elena Lazăr, Mărioara Cornianu, Alis Dema, Camelia Gurban Vidita, Atena Găluşcan.   

Abstract

Warthin tumor was first described in the American literature, by Aldred Warthin, in 1929, the pathologist who named this tumor papillary cystadenoma lymphomatosum, but since than it was also knew as adenolymphoma, cystadenolymphoma, and Warthin tumor. Because of its microscopically appearance and unknown origin, this tumor entity is still fascinating head and neck surgeons and pathologist. We evaluate the histopathological aspect of Warthin tumors using Hematoxylin-Eosin stain, and immunohistochemical and histological techniques. We reviewed the medical record of patients with salivary gland tumors diagnosed at County Hospital of Timisoara from 2002-2008. In six years, 22 cases with Warthin tumor were diagnosed and among them 17 men and five women, with average age 58.47. The analysis showed that 77.27% of Warthin tumors occurred in men, and the main histopathological aspect was with 50% epithelial component. The stromal component showed a prominent B-cell population by staining with CD20, and histological techniques for mucin were positive, and reticulin fibers were revealed while using Gordon-Sweets stain. The standard and the histological and immunohistochemical techniques highlighted the complex and variable microscopical appearance of Warthin tumor that the pathologist should consider when a diagnosis for this tumor is to be considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19434322

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  10 in total

1.  [Nasopharyngeal space-occupying lesion with middle ear effusion. Malignant or benign?].

Authors:  M von Laffert; R Arsenic; H Olze; M Dietel; F C Uecker
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

2.  Expression of the chemokine CCL28 in pleomorphic adenoma and adenolymphoma of the human salivary glands.

Authors:  Guo-Xin Liu; Jing Lan; Ying Sun; Yi-Jun Hu; Guang-Shui Jiang
Journal:  Exp Ther Med       Date:  2012-04-11       Impact factor: 2.447

3.  Unilateral Warthin's tumour in a patient of Afro-Caribbean descent.

Authors:  Ki Quintyne; F Wallis; V Healy; N Shine
Journal:  BMJ Case Rep       Date:  2014-06-02

4.  Human α-defensin (DEFA) gene expression helps to characterise benign and malignant salivary gland tumours.

Authors:  Jochen Winter; Annette Pantelis; Dominik Kraus; Jan Reckenbeil; Rudolf Reich; Soeren Jepsen; Hans-Peter Fischer; Jean-Pierre Allam; Natalija Novak; Matthias Wenghoefer
Journal:  BMC Cancer       Date:  2012-10-11       Impact factor: 4.430

5.  Mycobacterium Tuberculosis Infection within a Warthin Tumor: A Case Report and Literature Review.

Authors:  Murat Ulusan; Yasin Abul; Sule Bakır
Journal:  N Am J Med Sci       Date:  2013-10

6.  Role of fine-needle aspiration cytology in the diagnosis of major salivary gland tumors: A study with histological and clinical correlation.

Authors:  Archana Shetty; V Geethamani
Journal:  J Oral Maxillofac Pathol       Date:  2016 May-Aug

Review 7.  Cytologic diagnosis of parotid gland Warthin tumor: Systematic review and meta-analysis.

Authors:  Roie Fisher; Ohad Ronen
Journal:  Head Neck       Date:  2022-05-18       Impact factor: 3.821

8.  Diagnostic difficulties in fine needle aspiration of benign salivary glandular lesions.

Authors:  Hye Jung Jo; Hyo Jung Ahn; Soojin Jung; Hye-Kyoung Yoon
Journal:  Korean J Pathol       Date:  2012-12-26

9.  Adenolymphoma: A probing entity: Case report and review.

Authors:  Anand Pratap Singh; Ankita Tandon; Aman Chowdhary; Sheetal Mujoo
Journal:  J Nat Sci Biol Med       Date:  2013-07

10.  Warthin's tumour of the parotid gland: our experience.

Authors:  T C Chulam; A L Noronha Francisco; J Goncalves Filho; C A Pinto Alves; L P Kowalski
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-12       Impact factor: 2.124

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.